Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
17
Aug |
Three Genetic Variants Linked To Common Childhood Leukemia FoundCategory: Lymphoma / Leukemia | Leave a Comment |
UK scientists have for the first time found three genetic variants that raise children’s risk of developing acute lymphoblastic leukaemia (ALL), the most common childhood cancer. The discovery should help us to understand more about how ALL develops, they said. Scientists from the Institute of Cancer Research (ICR) found the three variants by comparing the DNA of heatlhy patients to patients with ALL.
|
24
Mar |
U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis SystemCategory: Lymphoma / Leukemia | Leave a Comment |
Therakos, Inc., a pioneer in immune cell therapy, announced the U.S. Food and Drug Administration (FDA) approval of the THERAKOS(TM) CELLEX(TM) Photopheresis System for the palliative (reducing the severity of symptoms) treatment of the skin manifestations (appearance) of cutaneous T-cell lymphoma (CTCL) that are unresponsive to other forms of treatment.
|
16
Mar |
Ipsogen Announces The CE Marking Of Its “ProfileQuant(R) WT1″ KitCategory: Lymphoma / Leukemia | Leave a Comment |
IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemias, announces the CE marking of its ProfileQuant(R) WT1 kit. The WT1 (for “Wilms’ tumor gene”) biomarker is used in the prognosis and follow-up of normal karyotype AML patients, who account for nearly half of AML adult patients.
|
16
Mar |
Ipsogen Announces The CE Marking Of Its “ProfileQuant(R) WT1″ KitCategory: Lymphoma / Leukemia | Leave a Comment |
IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemias, announces the CE marking of its ProfileQuant(R) WT1 kit. The WT1 (for “Wilms’ tumor gene”) biomarker is used in the prognosis and follow-up of normal karyotype AML patients, who account for nearly half of AML adult patients.
|
28
Dec |
Paediatric Patient Treated Using RapidArc™ Radiotherapy Technology In SwitzerlandCategory: Lymphoma / Leukemia | Leave a Comment |
A Swiss cancer clinic is among the first in the world to use a new, faster radiotherapy technology from Varian Medical Systems (NYSE: VAR) to treat a child patient. A 12-year-old girl with Hodgkin’s lymphoma was treated using Varian’s RapidArc™ technique at the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona.
|
19
Aug |
Asuragen, Inc. Launches Signature® NPM1 Mutations (RUO): A Rapid Multiplex Assay For The Detection Of NPM1 MutationsCategory: Lymphoma / Leukemia | Leave a Comment |
Asuragen, Inc. announced the launch of Signature® NPM1 Mutations (RUO), a multiplex reverse transcription PCR (RT-PCR) assay that enables the detection of NPM1 mutations. Asuragen’s Signature® NPM1 Mutations is a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin (NPM1) gene. Asuragen is one of two exclusive licensees to NPM1.